Based on a published report, in NSCLC patients who are resistant to first-generation EGFR TKIs, HER2 amplification can occur during acquisition of drug resistance in approximately 12% of patients, and is mutually exclusive with the EGFR T790M mutation17. This evidence concerns the gene EGFR and non-small cell lung carcinoma.